Evidence map›Paper›PMID 40061727›Full record

ArticleJournal of pharmacy & bioallied sciences2024

Hypermagnesemia with Dystonia Type 2: Case Report of a New SLC30A10 Variant.

Fahad Alamr, Hadeel M Alzahrani, Meelaf A Alhomrani, Abdulrhman S Alzhrani, Ayan Adel Abdullah Alghamdi, Atheer Awadh Alharthi

Abstract readCase Reports
In one paragraph

Article in Journal of pharmacy & bioallied sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fahad AlamrDepartment of Pediatric Hematology Oncology, Al-Baha University, Saudi Arabia.
Hadeel M AlzahraniDepartment of Pediatric, Children Hospital, Taif, Saudi Arabia.
Meelaf A AlhomraniThe General Directorate of Health Affairs in Al-Baha Region, Al-Baha, Saudi Arabia.
Abdulrhman S AlzhraniDepartment of Pediatric, King Fahad Hospital, Al-Baha, Saudi Arabia.
Ayan Adel Abdullah AlghamdiDepartment of Pediatric, Riyadh First Health Cluster, Saudi Arabia.
Atheer Awadh AlharthiDepartment of Pediatric, Children Hospital, Taif, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Manganese-induced neurological disorder (HMNDYT1) is a rare condition characterized by the accumulation of manganese in the brain, leading to neurological symptoms such as difficulties in walking. This disorder arises due to genetic mutations affecting manganese transport and metabolism. Presented is the case of a 5-year-9-month-old female from the south region, evaluated for walking difficulties. Born to non-consanguineous parents, her early developmental milestones were typical. However, her initial workup revealed polycythemia and hypermagnesemia, with significantly elevated manganese concentrations in whole blood (880 μg/L). Whole exome sequencing identified a novel missense homozygous variant (c. 137C>A p.(Ser46Tyr)) in the SLC30A10 gene, classified as a variant of uncertain significance (class 3) by the ACMG scheme. Furthermore, both parents were carriers of a heterozygous missense pathogenic variant (c. 1336G>C p.(Asp446His)) in the HMNDYT1 gene. MRI results confirmed manganese deposition in the basal ganglia and other brain regions. Management included biweekly phlebotomies for polycythemia and oral iron supplementation to reduce hypermagnesemia absorption. After two months, the patient was scheduled to be reviewed for CBC, LFT, RFT, MRI, and bone profile analysis.

Indexed as

Basal ganglia pathologygenetic disorderspediatric neurologypolycythemia managementwhole exome sequencing

Identifiers

PMID40061727
PMCPMC11888724

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.